Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐ CD 20 monoclonal antibody for the desensitization of candidates for renal transplant-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐ CD 20 monoclonal antibody for the desensitization of candidates for renal transplant

Published:2019-07-23 Issue:11 Volume:19 Page:3035-3045
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Redfield Robert R.¹,Jordan Stanley C.²,Busque Stephan³,Vincenti Flavio⁴,Woodle E. Steve⁵,Desai Niraj⁶,Reed Elaine F.⁷,Tremblay Simon⁵^ORCID,Zachary Andrea A.⁶,Vo Ashley A.²,Formica Richard⁸,Schindler Thomas⁹,Tran Ha¹⁰,Looney Caroline¹⁰,Jamois Candice¹⁰,Green Cherie¹⁰,Morimoto Alyssa¹⁰,Rajwanshi Richa¹⁰,Schroeder Aaron¹⁰,Cascino Matthew D.¹⁰,Brunetta Paul¹⁰,Borie Dominic¹⁰

Affiliation:

1. University of Wisconsin Madison Wisconsin

2. Cedars‐Sinai Medical CenterLos Angeles California

3. Stanford University Medical Center Stanford California

4. University of California San Francisco California

5. University of Cincinnati College of Medicine Cincinnati Ohio

6. Johns Hopkins University School of Medicine Baltimore Maryland

7. David Geffen School of MedicineUniversity of California Los Angeles California

8. Yale School of Medicine New Haven Connecticut

9. F. Hoffmann‐La Roche Basel Switzerland

10. Genentech, Inc. South San Francisco California

Funder